Bulletin: BioMark receives $825K grant for its cancer detection technology

Their goal is to develop a low-cost, high-throughput test that will make early-stage lung cancer screening feasible and affordable for at-risk populations.

BioMark Diagnostic Solutions Inc. announced that it received $825,000 to develop an early-stage lung cancer screening test using its proprietary liquid biopsy platform. The funding is being provided by the Consortium for Industrial Research and Innovation in Medical Technology (MEDTEQ+), the Canadian Cancer Society, the Canadian Institutes of Health Research - Institute of Cancer Research, and Brain Canada Foundation.

The funding is going to an initiative entitled “A Pan Canadian initiative for the development of a liquid biopsy assay for lung cancer screening,” and is being led by Dr. Philippe Joubert and a team of leading clinicians, academic researchers, and data scientists.

The grant is part of a two-year initiative through which BioMark, in collaboration with Phytronix Technologies Inc., and researchers from the Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, the Metabolomics Innovation Centre, Saint-Boniface Research Center and the CHU de Québec - Université Laval, will be validating the firm's liquid biopsy platform and proprietary biomarker panel for the detection of early-stage lung cancer in over 1,200 individual samples coming from the IUCPQ 's Quebec Respiratory Health Research Network site.

The overarching goal is to develop a low-cost, high-throughput test that will make early-stage lung cancer screening feasible and affordable for at-risk populations. The large sample size will help include important clinical parameters and identify additional metabolites that might be incorporated in the assay to further improve the test specificity.

“This is an important project for BioMark as it gears up for the introduction of lung cancer biomarkers that can be incorporated into a screening program across Canada, beginning in Quebec, and later globally,” said BioMark's CEO Rashid Ahmed Bux. “The teams are formed around a vibrant cluster which focus on validation and accelerated translation of the outcome to enable physicians to have better access to diagnostic tools designed to positively impact cancer care management. This cross pollination of team members will mitigate scientific risks and ultimately drive clinical adoption required for commercialization.”

Never miss an update. Receive stories like this once a week in your inbox by subscribing to the Sunday Briefing.